Blair William & Co. IL Purchases Shares of 3,000 Puma Biotechnology Inc (PBYI)

Blair William & Co. IL acquired a new stake in Puma Biotechnology Inc (NYSE:PBYI) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $262,000.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Puma Biotechnology by 2.4% in the first quarter. FMR LLC now owns 3,540,729 shares of the biopharmaceutical company’s stock worth $131,715,000 after buying an additional 81,410 shares during the period. Wellington Management Group LLP increased its stake in shares of Puma Biotechnology by 7.2% in the first quarter. Wellington Management Group LLP now owns 2,539,350 shares of the biopharmaceutical company’s stock worth $94,464,000 after buying an additional 170,812 shares during the period. Vanguard Group Inc. increased its stake in shares of Puma Biotechnology by 4.4% in the first quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock worth $90,355,000 after buying an additional 101,722 shares during the period. Redmile Group LLC increased its position in Puma Biotechnology by 33.7% during the 1st quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after purchasing an additional 435,274 shares during the period. Finally, Schroder Investment Management Group increased its position in Puma Biotechnology by 22.8% during the 1st quarter. Schroder Investment Management Group now owns 803,926 shares of the biopharmaceutical company’s stock valued at $30,147,000 after purchasing an additional 149,205 shares during the period. Institutional investors own 80.98% of the company’s stock.

Shares of Puma Biotechnology Inc (NYSE:PBYI) traded down 0.58% during mid-day trading on Friday, reaching $102.75. The company had a trading volume of 72,066 shares. The stock’s 50-day moving average price is $89.38 and its 200 day moving average price is $65.55. The company’s market capitalization is $3.82 billion. Puma Biotechnology Inc has a 1-year low of $28.35 and a 1-year high of $109.85.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78). Equities analysts expect that Puma Biotechnology Inc will post ($8.67) EPS for the current year.

PBYI has been the topic of a number of research analyst reports. J P Morgan Chase & Co reissued an “overweight” rating and set a $89.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, May 24th. Stifel Nicolaus reissued a “buy” rating and set a $110.00 price objective (down from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. Zacks Investment Research downgraded shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Cowen and Company reaffirmed a “market perform” rating on shares of Puma Biotechnology in a research report on Monday, May 22nd. Finally, BidaskClub downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $110.70.

In other news, SVP Richard Paul Bryce sold 5,000 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the transaction, the senior vice president now owns 34,237 shares of the company’s stock, valued at approximately $2,982,042.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alan H. Auerbach sold 13,175 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total value of $1,248,067.75. Following the completion of the transaction, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,173 shares of company stock valued at $3,373,689. 22.70% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://baseballnewssource.com/markets/blair-william-co-il-takes-position-in-puma-biotechnology-inc-pbyi/1601295.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.